Future of nanomedicines for treating respiratory diseases

References

• Agent P, Parrott H. Inhaled therapy in cystic fibrosis: agents, devices and regimens. Breathe. 2015;11:111–118.
   Web of Science ®Google Scholar
• Pham D D, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm. 2015;478:517–529.
   PubMed Web of Science ®Google Scholar
• Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther. 2012;6:19–28.
   PubMed Web of Science ®Google Scholar
• Rafii R, Juarez MM, Albertson TE, et al. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis. 2013;5:48–73.
   PubMed Web of Science ®Google Scholar
• Donahoe M. Acute respiratory distress syndrome: A clinical review. Pulm Circ. 2011;1:192–211.
   PubMedGoogle Scholar
• Broadbent L, Groves H, Shields MD, et al. Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses. 2015;9:169–178.
   PubMed Web of Science ®Google Scholar
• Mejias A, Ramilo O. New options in the treatment of respiratory syncytial virus disease. J Infect. 2015;71:S80–S7.
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Mainelis G, Taratula O, et al. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol Med. 2014;11:44–55.
   PubMedGoogle Scholar
• Hickey AJ. Controlled delivery of inhaled therapeutic agents. J Control Release. 2014;190:182–188.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497–1504.
   PubMed Web of Science ®Google Scholar
• Cipolla D, Gonda I. Formulation technology to repurpose drugs for inhalation delivery. Drug Discov Today Ther Strateg. 2011;8:123–130.
   Google Scholar
• Yang W, Peters JI, Williams RO III. Inhaled nanoparticles - a current review. Int J Pharm. 2008;356:239–247.
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74.
   PubMed Web of Science ®Google Scholar
• Commission recommendation on the definition of nanomaterial. Off J Eur Union. 2011;L275/38–40.
   Google Scholar
• Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine. 2014;4357–4373.
   PubMed Web of Science ®Google Scholar
• Koopaei NN, Adbollahi M. Opportunities and obstacles to the development of nanopharmaceuticals for human use. DARU J Pharma Sci. 2016;24. DOI:10.1186/s40199-016-0163-8.
   Web of Science ®Google Scholar
• Mansour HM, Rhee Y-S, Xiao W. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;299–319.
   PubMed Web of Science ®Google Scholar
• Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol. 2009;124:S88–S93.
   PubMed Web of Science ®Google Scholar
• Scherließ R, Etschmann C. DPI formulations for high dose applications - challenges and opportunities. Int J Pharm. 2018;548:49–53.
   PubMedGoogle Scholar
• Yameen B, Choi WI, Vilos C, et al. Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release. 2014;190:485–499.
   PubMed Web of Science ®Google Scholar
• Amani A, York P, Chrystyn H, et al. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. AAPS PharmSciTech. 2010;11:1147–1151.
   PubMed Web of Science ®Google Scholar
• Newman S. Respiratory drug delivery: essential theory and practice. Richmond, Virginia: RDD online; 2009.
   Google Scholar
• Telko MJ, Hickey JA. Dry powder inhaler formulation. Resp Care. 2005;50:1209–1227.
   PubMedGoogle Scholar
• Blank F, Fytianos K, Seydoux E, et al. Interaction of biomedical nanoparticles with the pulmonary immune system. J Nanobiotechnology. 2017;15(6).
   Web of Science ®Google Scholar
• Blank F, Stumbles P, von Garnier C. Opportunities and challenges of the pulmonary route for vaccination. Expert Opin Drug Deliv. 2011;8:547–563.
   PubMed Web of Science ®Google Scholar
• Ungaro F, D’ Angelo I, Miro A, et al. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol. 2012;64:1217–1235.
   PubMed Web of Science ®Google Scholar
• Murgia X, de Souza Carvalho C, Lehr C-M. Overcoming the pulmonary barrier: new insights to improve the efficiency of inhaled therapeutics. Eur J Nanomed. 2014;6:157–169.
   Google Scholar
• Lai SK, Y-Y W, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61:158–171.
   PubMed Web of Science ®Google Scholar
• Alpar HO, Somavarapu S, Atuah KN, et al. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev. 2005;57:411–430.
   PubMed Web of Science ®Google Scholar
• Schneider CS, Xu Q, Boylan NJ, et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv. 2017;3:e1601556.
   PubMed Web of Science ®Google Scholar
• Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P&T. 2017;42:742–755.
   PubMedGoogle Scholar
• Barenholz YC. Doxil® — the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Heneweer C, Gendy SE, Peñate-Medina O. Liposomes and inorganic nanoparticles for drug delivery and cancer imaging. Ther Deliv. 2012;3:645–656.
   PubMedGoogle Scholar
• Speer CP, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1995;72:F8–13.
   PubMed Web of Science ®Google Scholar
• Carvalho TC, Peters JI, Williams RO III. Influence of particle size on regional lung deposition––what evidence is there? Int J Pharm. 2011;406:1–10.
   PubMed Web of Science ®Google Scholar
• Aragão-Santiago L, Bohr A, Delaval M, et al. Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome. Curr Pharm Des. 2016;22:1147–1160.
   PubMed Web of Science ®Google Scholar
• Sivadas N, O’Rourke D, Tobin A, et al. A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm. 2008;358:159–167.
   Google Scholar
• Learoyd TP, Burrows JL, French E, et al. Sustained delivery by leucine-modified chitosan spray-dried respirable powders. Int J Pharm. 2009;372:97–104.
   PubMed Web of Science ®Google Scholar
• Raula J, Eerikäinen H, Peltonen L, et al. Aerosol-processed polymeric drug nanoparticles for sustained and triggered drug release. J Control Release. 2010;148:e52–3.
   PubMed Web of Science ®Google Scholar
• Mukherjee B, Satra K, Pattnaik G, et al. Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomedicine. 2008;3:487–496.
   PubMed Web of Science ®Google Scholar
• Cipolla D, Blanchard J, Gonda I.Development of liposomal ciprofloxacin to treat lung infections.Pharmaceutics.2016;8.
   PubMed Web of Science ®Google Scholar
• Olivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195:814–823.
   PubMed Web of Science ®Google Scholar
• Mönckedieck M, Kamplade J, Littringer EM, et al. Spray drying tailored mannitol carrier particles for dry powder inhalation with differently shaped active pharmaceutical ingredients. In: Fritsching U, editor. Process-spray: functional particles produced in spray processes. Switzerland: Springer International Publishing; 2016. p. 517–566.
   Google Scholar
• Ingvarsson PT, Schmidt ST, Christensen D, et al. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01. J Control Release. 2013;167:256–264.
   PubMed Web of Science ®Google Scholar
• Janke J, Scherließ R. Vaccination via the respiratory tract - porous PLGA-nanoparticles for a faster release. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; Lisbon; 2014.
   Google Scholar
• Parumasivam T, Chang RYK, Abdelghany S, et al. Dry powder inhalable formulations for anti-tubercular therapy. Adv Drug Deliv Rev. 2016;102:83–101.
   PubMed Web of Science ®Google Scholar
• Sung JC, Padilla DJ, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009;26. DOI:10.1007/s11095-009-9894-2.
   PubMed Web of Science ®Google Scholar
• Suarez S, O’Hara P, Kazantseva M, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48:431–434.
   PubMed Web of Science ®Google Scholar
• O’Hara P, Hickey A. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterisation. Pharm Res. 2000;17:955–961.
   PubMed Web of Science ®Google Scholar
• Baleeiro RB, Schweinlin M, Rietscher R, et al. Nanoparticle-based mucosal vaccines targeting tumor-associated antigens to human dendritic cells. J Biomed Nanotechnol. 2016;12:1–17.
   PubMed Web of Science ®Google Scholar
• Scherließ R, Diedrich A, Ebensen T, et al. Chitosan nanoparticulate formulation for pulmonary vaccination––formulation and in vivo proof of concept. In: Dalby R, editor. Respiratory drug delivery Europe. Antibes, France: Davies Healthcare International Publishing; 2015:269–274.
   Google Scholar
• Tafaghodi M, Rastegar S. Preparations and in vitro study of dry powder microspheres for nasal immunization. J Drug Target. 2010;18:235–242.
   PubMed Web of Science ®Google Scholar
• Trows S, Scherließ R. Preparation and characterization of dry powder agarose nano-in-microparticles for nasal vaccination. In: Dalby RN, editor. Respiratory drug delivery 2012. Phoenix, AZ: Davies Healthcare International Publishing; 2012. p. 491–496.
   Google Scholar
• Depreter F, Pilcer G, Amighi K. Inhaled proteins: challenges and perspectives. Int J Pharm. 2013;447:251–280.
   PubMed Web of Science ®Google Scholar
• Grenha A, Remunan-Lopez C, Carvalho ELS, et al. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm. 2008;69:83–93.
   PubMed Web of Science ®Google Scholar
• Grenha A, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci. 2005;25:427–437.
   PubMed Web of Science ®Google Scholar
• Wang N, Wu XS. Preparation and characterization of agarose hydrogel nanoparticles for protein and peptide drug delivery. Pharm Dev Technol. 1997;2:135–142.
   PubMedGoogle Scholar
• Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: a review. Int J Mol Sci. 2014;15:5852–5873.
   PubMed Web of Science ®Google Scholar
• Youngren-Ortiz SR, Gandhi NS, España-Serrano L, et al. Aerosol delivery of siRNA to the lungs. Part 2: nanocarrier-based delivery systems. Kona. 2017;34:44–69.
   PubMedGoogle Scholar
• Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012;12:592–605.
   PubMed Web of Science ®Google Scholar
• Chadwick S, Kriegel C, Amiji MM. Delivery strategies to enhance mucosal vaccination. Expert Opin Biol Ther. 2009;9:427–440.
   PubMed Web of Science ®Google Scholar
• Malyala P, Singh M. Micro/nanoparticle adjuvants: preparation and formulation with antigens. In: Davies G, editor. Vaccine adjuvants. New York (NY): Springer Science+Business Media, LCC; 2010. p. 91–101.
   Google Scholar
• Li X, Sloat BR, Yanasarn N, et al. Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. Eur J Pharm Biopharm. 2011;78:107–116.
   PubMed Web of Science ®Google Scholar
• Chadwick S, Kriegel C, Amiji MM. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev. 2010;62:394–407.
   PubMed Web of Science ®Google Scholar
• Slütter B, Plapied L, Fievez V, et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release. 2009;138:113–121.
   PubMed Web of Science ®Google Scholar
• Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. Aaps J. 2013;15:85–94.
   PubMed Web of Science ®Google Scholar
• Amorij J-P, Saluja V, Petersen AH, et al. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine. 2007;25:8707–8717.
   PubMedGoogle Scholar
• Saluja V, Amorij J-P, Kapteyn JC, et al. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release. 2010;144:127–133.
   PubMed Web of Science ®Google Scholar
• Audouy SAL, van der Schaaf G, Hinrichs WLJ, et al. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine. 2011;29:4345–4352.
   PubMedGoogle Scholar
• Cape SP, McAdams DH, Manion J, et al. Inhalable dry powder live-attenuated measles virus vaccine prepared by the CAN-BD process, a novel spray drying alternative to lyophilisation. CHI PepTalk; San Diego, CA; 2010.
   Google Scholar
• de Swart RL, Kuiken T, Fernandez-de Castro J, et al. Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine. 2006;24:6424–6436.
   PubMed Web of Science ®Google Scholar
• Kisich KO, Higgins MP, Park I, et al. Dry powder measles vaccine: particle deposition, virus replication, and immune response in cotton rats following inhalation. Vaccine. 2011;29:905–912.
   PubMed Web of Science ®Google Scholar
• Lin W-H, Griffin DE, Rota PA, et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Pnas. 2011;108:2987–2992.
   PubMed Web of Science ®Google Scholar
• Hanif SNM, Garcia-Contreras L. Pharmaceutical aerosols for the treatment and prevention of Tuberculosis. Front Cell Infect Microbiol. 2012;2:1–11.
   PubMed Web of Science ®Google Scholar
• van Dissel JT, Joosten SA, Hoff ST, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 2014;32:7098–7107.
   PubMed Web of Science ®Google Scholar
• Muttil P, Prego C, Garcia-Contreras L, et al. Immunization of guinea pigs with novel hepatitis b antigen as nanoparticle aggregate powders administered by the pulmonary route. Aaps J. 2010;12:330–337.
   PubMed Web of Science ®Google Scholar
• Tonnis WF, Kersten GF, Frijlink HW, et al. Pulmonary vaccine delivery: a realistic approach? J Aerosol Med Pulm Drug Deliv. 2012;25:249–260.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685–696.
   PubMed Web of Science ®Google Scholar
• Medimmune. FluMist prescription information. 2012.
   Google Scholar
• Dhere R, Yeolekar L, Kulkarni P, et al. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine. 2011;29:A16–A21.
   PubMed Web of Science ®Google Scholar
• Sullivan VJ, Mikszta JA, Laurent P, et al. Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin Drug Deliv. 2006;3:87–95.
   PubMedGoogle Scholar
• Hirota K, Terada H. Endocytosis of particle formulations by macrophages and its application to clinical treatment. In: Ceresa B, editor. Molecular regulation of endocytosis. InTech; 2012. p. 413–428. doi:10.5772/45820 .
   Google Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173:3148–3154.
   PubMed Web of Science ®Google Scholar
• Rietscher R, Schröder M, Janke J, et al. Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity. Eur J Pharm Biopharm. 2016;102:20–31.
   PubMed Web of Science ®Google Scholar
• Hanefeld A, Weigandt M, Wolf M, et al., inventors; Merck Patent Gesellschaft, assignee. Antigen-loaded chitosan nanoparticles for immunotherapy patent WO2015/185180A1. 2014 06.
   Google Scholar
• Scherließ R, Mönckedieck M, Young K, et al. First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice. Int J Pharm. 2015;479:408–415.
   PubMed Web of Science ®Google Scholar
• Pereira GG, Lawson AJ, Buttini F, et al. Loco-regional administration of nanomedicines for the treatment of lung cancer. Drug Deliv. 2016;23:2881–2896.
   PubMed Web of Science ®Google Scholar
• Lee W-H, Loo C-Y, Traini D, et al. Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges. Asian J Pharm Sci. 2015;10:481–489.
   Web of Science ®Google Scholar
• Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-Nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res. 2004;10:2319–2326.
   PubMed Web of Science ®Google Scholar
• Rudokas M, Najlah M, Alhnan MA, et al. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med Princ Pract. 2016;25:60–72.
   PubMed Web of Science ®Google Scholar
• Videira M, Almeida AJ, Fabra À. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine. 2012;8:1208–1215.
   PubMed Web of Science ®Google Scholar
• Long J-T, Cheang T-Y, Zhuo S-Y, et al. Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis. J Nanobiotechnology. 2014;12.
   PubMed Web of Science ®Google Scholar
• De Crozals G, Bonnet R, Farre C, et al. Nanoparticles with multiple properties for biomedical applications: a strategic guide. Nano Today. 2016;11:435–463.
   Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Fokkink R, et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release. 2010;144:118–126.
   PubMed Web of Science ®Google Scholar
• Wöll S, Conrad L, Swee LK, et al. Sortaggable liposomes: evaluation of reaction conditions for single-domain antibody conjugation by Sortase A and targeting of CD11b+ myeloid cells. Eur J Pharm Biopharm. 2018;133:138–150.
   PubMed Web of Science ®Google Scholar
• Diedrich A, Scherließ R. Stability of a respirable dry powder vaccine. Proceedings of DDL 25. Edinburgh, Scotland; 2014:224–227.
   Google Scholar
• Heidland J, Scherließ R. Nano-in-microparticles for dry powder vaccination via the respiratory tract. CRS local chapter Germany annual meeting. Marburg; 2017.
   Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999–1022.
   PubMed Web of Science ®Google Scholar
• Anton N, Jakhmola A, Vandamme TF. Trojan Microparticles for Drug Delivery. Pharmaceutics. 2012;4:1–25.
   PubMedGoogle Scholar
• Pulliam B, Sung JC, Edwards DA. Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin Drug Deliv. 2007;4:651–663.
   PubMed Web of Science ®Google Scholar
• Oberdörster G, Sharp Z, Atudorei V, et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol. 2004;16:437–445.
   PubMed Web of Science ®Google Scholar
• Fröhlich E, Salar-Behzadi S. Toxicological assessment of inhaled nanoparticles: role of in vivo, ex vivo, in vitro, and in silico studies. Int J Mol Sci. 2014;15:4795–4822.
   PubMed Web of Science ®Google Scholar
• Dailey LA, Jekel N, Fink L, et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol. 2006;215:100–108.
   PubMed Web of Science ®Google Scholar
• Jones M-C, Jones SA, Riffo-Vasquez Y, et al. Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility. J Control Release. 2014;183:94–104.
   PubMed Web of Science ®Google Scholar
• Woods A, Patel A, Spina D, et al. In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug delivery. J Control Release. 2015;210:1–9.
   PubMed Web of Science ®Google Scholar
• Kumar A, Bicer EM, Pfeffer P, et al. Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans. Nanomedicine. 2017;13:2517–2521.
   PubMed Web of Science ®Google Scholar
• Kumar A, Bicer EM, Morgan A, et al. Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid. Nanomedicine. 2016;12:1033–1043.
   PubMed Web of Science ®Google Scholar